Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer

Br J Cancer. 1991 May;63(5):763-4. doi: 10.1038/bjc.1991.170.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / blood
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Drug Evaluation
  • Estradiol / blood
  • Female
  • Follicle Stimulating Hormone / blood
  • Humans
  • Imidazoles / therapeutic use*
  • Imidazolidines*
  • Luteinizing Hormone / blood
  • Menopause*
  • Middle Aged
  • Sex Hormone-Binding Globulin / analysis

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Imidazolidines
  • Sex Hormone-Binding Globulin
  • Estradiol
  • nilutamide
  • Luteinizing Hormone
  • Follicle Stimulating Hormone